]. In the present study, we have expressed rat kallikrein-binding protein in Escherichia coli with a T7-polymerase/promoter expression system. A high level of expression was detected by an e.l.i.s.a. with an average of 24.2 mg of recombinant rat kallikrein-binding protein per 1 of culture. The recombinant protein appeared as a major protein in a crude extract of Escherichia coli on SDS/ PAGE. It showed a molecular mass of43 kDa and was recognized by polyclonal antibody to the native rat kallikrein-binding protein in Western-blot analysis. The recombinant rat kallikreinbinding protein has been purified to apparent homogeneity by DEAE-Sepharose CL-6B, hydroxyapatite Bio-Gel HPHT and Mono P 5/5 column chromatography. The purified recombinant rat kallikrein-binding protein showed immunological identity with the native rat kallikrein-binding protein purified from rat serum, in a specific e.l.i.s.a. To confirm the fidelity of the expression, the N-terminal ten amino acids of the recombinant rat kallikrein-binding protein were sequenced and were shown to match perfectly with those of the native rat kallikrein-binding protein. The purified recombinant rat kallikrein-binding protein formed SDS-and heat-stable complexes with rat tissue kallikrein (rKl) and T-kininogenase (rKl0) in vitro, but not with other enzymes in the rat kallikrein gene family, such as tonin (rK2) and S3 protein (rK9), which indicates enzyme-specific binding. The properties of the recombinant rat kallikrein-binding protein including its size, charge, complex formation with target enzymes and immunological characteristics were compared with those of the native protein. This expression system provides a simple way to obtain a large amount of the biologically active recombinant protein, to study structure-function relationships of the rat kallikrein-binding protein and its interaction with its target enzymes.
INTRODUCTION
Tissue kallikrein (EC 3.4.21.35 ) is known to process kininogens and release vasoactive kinins by limited proteolysis (Fielder, 1979) . The kallikrein-kinin system is involved in many physiological and pathophysiological processes, including the regulation of blood pressure and local blood flow, and smooth muscle contraction and relaxation (Cuthbert and Margolius, 1982; Schachter, 1980; Bhoola et al., 1992) . The activity of tissue kallikrein is regulated both post-translationally and at the level of gene expression (Murray et al., 1990) . For many years, human al-antitrypsin was the only known potential inhibitor of human tissue kallikrein present in serum (Geiger et al., 1981) . However human al-antitrypsin is a slow progressive inhibitor of tissue kallikrein and therefore is not considered to be a physiological regulator of tissue kallikrein.
In a previous study, we purified rat kallikrein-binding protein (RKBP) to homogeneity. It is an acidic glycoprotein with a molecular mass of 60 kDa . Its cDNA and gene have been cloned and sequenced and this demonstrated that RKBP is distinct from the known serine-proteinase inhibitors, although it shares a high degree of sequence similarity with acantichymotrypsin, al-antitrypsin and antithrombin III Chai et al., 1991) . It forms a complex with rat tissue kallikrein at a molar ratio of 1: 1 and the complex is resistant to SDS and to heat treatment, indicating a covalent linkage between rat tissue kallikrein and RKBP. Recently we have identified and purified a novel kallikrein inhibitor in human serum that forms a complex with human tissue kallikrein (Chao et al., 1986 Chen et al., 1990; Zhou et al., 1992) . In vivo clearance studies in rats showed that binding to human kallikrein-binding protein prolongs the half life of kallikrein and may play a role in regulating the bioavailability of tissue kallikrein . Therefore kallikrein-binding protein is regarded as a potential tissue-kallikrein inhibitor that modulates the activity of tissue kallikrein at the post-translational level (Murray et al., 1990) .
Although the physiological function of kallikrein-binding protein has not been elucidated, the evidence accumulated so far suggests that RKBP may be important for pathophysiological processes. For example, spontaneously hypertensive rats have lower mRNA and protein levels ofRKBP compared with WistarKyoto (WKY) normotensive rats (Chao and Chao, 1988; Chao et al., 1992) . Restriction-fragment-length polymorphisms (RFLP) have been observed in the RKBP gene between spontaneously hypertensive and Wistar-Kyoto rats . These findings indicate that RKBP may contribute to the hypertensive phenotype in spontaneously hypertensive rats. In 826 J.-x. Ma and others addition, the expression of RKBP gene is induced markedly by growth-hormone treatment and the RKBP mRNA levels are correlated with the growth rate of the rats, suggesting that RKBP may play a role in growth and development (Berry and Seelig, 1984; Yoon et al., 1987 Yoon et al., , 1990 . During acute-phase inflammation, RKBP expression levels are reduced, indicating a potential involvement of RKBP in inflammatory responses (Le Cam and Le Cam, 1987; Schwarzenberg et al., 1989; Chao et al., 1990) .
In order to elucidate the biological functions of kallikreinbinding protein and its interaction with tissue kallikrein, it is necessary to find a simple way to obtain kallikrein-binding protein in large. quantities and to establish a heterologousexpression system for structure-function studies by site-directed mutagenesis. In the present study we have expressed RKBP in an Escherichia coli strain with a T7-polymerase-promoter system and have obtained a high yield of active recombinant RKBP which has been characterized.
EXPERIMENTAL Materials
E. coli HB101/pGP1-2 is a strain of HB101 harbouring a vector containing gene 1 of T7 phage under the control of the inducible A PL and the gene for the heat-sensitive A repressor. Plasmid pET3b is a derivative of pBR322 that contains the T7 promoter (q 10) and the gene 10 translation-start site (slO) and transcription terminator (TO) (Studier and Moffatt, 1986) . Rat tissue kallikrein (rKl) and rat T-kininogenase (rKl0*), S3 protein (rK9) and tonin (rK2) (for nomenclature see Berg et al., 1992) were purified to homogeneity in this laboratory Wang et al., 1992) and were labelled with 1251 by the lactoperoxidase method (Shimamoto et al., 1980) . RKBP antibody was purified by a Protein A-affinity column as described previously (Chao et al., 1985) . The following materials were obtained from commercial sources: DEAE-Sepharose CL-6B, Protein A-Sepharose (Pharmacia); Taq DNA polymerase (BRL); polyethylenimine, iminodiacetic acid, peroxidase avidin, Coomassie Blue, rifampicin (Sigma); Ampoline (LKB) and molecular mass protein standards (Bio-Rad).
Construction of the RKBP expression vector
The scheme for constructing the RKBP expression vector is shown in Figure 1 . A full-length cDNA encoding RKBP had been screened from a rat-liver cDNA library and its nucleotide sequence had been determined previously (Chai et al., 1991) . To delete the nucleotide sequence that encoded the signal peptide, a polymerase chain reaction (PCR) was performed using the fulllength RKBP cDNA as the template. The 5' PCR primer (CATATGGATGGCATACTGGGAAGG) starts at the first codon of the mature protein of RKBP. Adjacent to the 5' end of the first codon is an unannealed NdeI site (underlined). The imported NdeI site in the PCR product not only served as a restriction site to facilitate cloning, but also as a translational initiation codon (ATG). The 3' primer (GGATCCTGGGCA-GAATTGTCAGATTTTGGGG) is complementary to the 3' untranslated sequence of the cDNA and contains a BamHI site. PCR products were synthesized with 30 cycles of PCR using Taq DNA polymerase. The single band of PCR product (1250 bp) was cloned into Ml3mpl9 by blunt-ended ligation and was sequenced to eliminate any potential mismatch that had been generated by the Taq DNA polymerase (Sanger et al., 1977) . No mismatch was found in the PCR-synthesized cDNA. It was then subcloned into the pET3b vector at the NdeI and BamHI sites, immediately downstream from the T7 promoter (Figure 1) .
Expression of the recombinant RKBP in E. coli and preparation of the cell extract The expression procedure was as described by Studier and Moffatt (1986) with some modifications. The pET3b vector containing RKBP cDNA was transformed into HB1O1/pGP1-2 cells, which harbour the pGPI-2 plasmid, expressing T7 polymerase. The transformed cells were grown in 2 x YT at 30°C with vigorous shaking overnight until the A590 reached 1.2. Expression was then induced by heating the culture to 42°C for 30 min, followed by adding rifampicin to a final concentration of 100 ,g/ml to block the transcription driven by the E. coli polymerase. The exclusive expression driven by the T7 polymerase was carried out at 37°C for an additional 2 h. The cells were harvested by centrifugation at 4000 g for 30 min. The cellpellet was washed with 10 mM Tris/HCl, pH 8.0 and was resuspended in a solution containing 10 mM Tris/HCl, pH 8.0, 1 mM EDTA and 1 ,ug/ml DNAase I. The cell lysate was prepared by three passages through a French pressure cell (SLM Instruments) at 1.1 x 105 kPa. Insoluble proteins and cell debris were removed by centrifugation at 10000 g for 2 h. The soluble E. coli extract was frozen at -20°C for further characterization.
SDS/PAGE SDS/PAGE was performed on a 7.5-15 % linear polyacrylamide gel, using the buffer system described by Laemmli (1970) 
Isoelectric focusing
Isoelectric focusing was performed essentially as previously described in an LKB-2117 Multiphor electrophoresis system with a pH gradient of 3.5-10.0, formed by Ampholine. The gel was run for 2.5 h at 4°C with a voltage increasing from 150-1450 V. After completion of focusing, the edge of the gel was removed and strips of 6 mm width were cut transversely at 4 mm intervals. Each section was placed in a tube containing 1 ml of distilled water and was incubated for 24 h, when the pH values of the sections were measured and the pH gradient was obtained by plotting the pH value of the sections against their original positions on the gel. The remaining gel was fixed in 25% (v/v) trichloroacetic acid overnight, stained in 0.2 % (w/v) Coomassie Blue solution for 15 min and destained in acetic acid/methanol/water (2:5:13, by vol.).
Western-blot analysis
The cell extract or purified RKBP was resolved on SDS/PAGE and was electrotransferred onto Immobilon-P membranes. The antigen-overlay method for immunoblotting has been described previously . In outline the membranes were blocked with BLOTTO solution [5 % (w/v) nonfat dry milk in 10 mM sodium phosphate, pH 7.4, 0.14 M NaCl, 1 1tM pphenylmethanesulphonyl fluoride, 1 mg/l thimerosal, 200 mg/l NaN3 and 0.01 % (w/v) antifoam A] for 1 h and were then incubated with rabbit anti-RKBP antiserum (1: 250 in BLOTTO solution) for 3 h with gentle shaking. The membranes were washed three times with BLOTTO, followed by incubation with The cDNA encoding the mature protein of RKBP was amplified by PCR and an Ndel (N) site was added at the 5' terminus. The PCR product was cloned into Ml3mpl9 for sequence verification and then was subcloned into the pET3b vector at the Ndel and BamHl (B) sites, immediately downstream from the T7 promoter. Abbreviations used: E, EcoRl; H, Hindll.
1251I-labelled RKBP for 1.5 h. The membranes were then washed three times with BLOTTO and once with phosphate-buffered saline (10 mM sodium phosphate, pH 7.4 and 0.14 M NaCI), were air-dried and were exposed to Kodak X-Omat film. All procedures were carried out at room temperature. RKBP e.I.I.s.a.
The 96-well plates, coated with Protein A affinity-purified rabbit anti-RKBP antibody (1 ,ug/ml), were blocked with 1 % (w/v) bovine serum albumin. An RKBP standard (0.3-25 ng/ml) or the samples to be determined were incubated in the wells at 37°C for 90 min. After the wells had been washed three times, biotinylated rabbit anti-RKBP antibody (1 ,ug/ml) was added to the wells and they were incubated at 37°C for 60 min. The wells were washed and 100 g1 of peroxidase-avidin (1,ug/ml) was incubated in the wells at 37°C for 30 min. Unbound peroxidaseavidin was removed by washing five times, the substrate was added and was incubated at room temperature for 30 min. The concentration of RKBP was determined by measuring the A414.
Purfflcation of RKBP from rat serum RKBP was purified from rat serum, as described previously, with some modifications . All steps were carried out at 4°C unless otherwise specified. Aliquots of 10 ml of rat sera were dialysed against 20 mM sodium-phosphate buffer, pH 7.0 and were then centrifuged at 10000 g for 10 min. The dialysed sera were applied onto an AffiGel-Blue column (2.5 cm x 20 cm) that had been equilibrated previously with 20 mM sodium-phosphate buffer, pH 7.0, containing 0.02 % (w/v) NaN3 at a flow rate of 10 ml/h. The column was washed with the same buffer until the absorbance at 280 nm reached the baseline. Fractions of 8 ml were collected. Flow-through fractions with kallikrein-binding activity were combined and were loaded directly onto a DEAE-Sepharose CL-6B column (1.5 cm x 20 cm) that had been equilibrated with 20 mM sodium-phosphate buffer, pH 7.0. The column was then washed with the same buffer and was eluted with 400 ml of gradient from 0 to 0.3 M NaCl, in 20 mM sodium-phosphate buffer, pH 7.0. Fractions of 8 ml were collected and fractions with kallikrein-binding activity were pooled, concentrated and were then dialysed against 20 mM sodium phosphate, pH 7.0. The dialysate was loaded slowly onto a hydroxyapatite Bio-Gel HT column (1.5 cm x 20 cm) that had been equilibrated with 20 mM sodium-phosphate buffer, pH 7.0. RKBP was in the flow-through fractions, which were combined, concentrated and were dialysed against 1.7 M (NH4)2SO4 in 40 mM sodium-phosphate buffer, pH 7.0. The sample was applied at room temperature at a flow rate of 0.5 ml/min onto a phenyl-Superose 5/5 column on a Pharmacia LKB f.p.l.c. system, with starting conditions of 1.7 M (NH4)2S04 in 40 mM sodiumphosphate buffer, pH 7.0 (eluent A). RKBP was separated from the protein contamination in a 30 ml gradient from 0 to 100 % (v/v) of eluent B (0.01 M sodium-phosphate buffer, pH 7.0). RKBP fractions were pooled, concentrated and were dialysed through a Centricon-30 with several changes of phosphate buffer and then were kept at -20°C before characterization.
Purffication of the recombinant RKBP from E. coli extract A sample of 60 ml of crude E. coli extract was precipitated with 0. I% (w/v) polyethylenimine. The pellet was removed by centrifugation at 10000 g for 10 min. The supernatant was dialysed against 20 mM sodium-phosphate buffer, pH 7.0, containing 0.02 % (w/v) NaN3 and then was applied onto a DEAESepharose CL-6B column (2.5 cm x 20 cm) that had been equilibrated with the same buffer. Unbound proteins were washed off with the same buffer until the absorbance at 280 nm reached the baseline. Bound proteins were eluted with 500 ml of gradient from 0 to 0.2 M NaCl, in 20 mM sodium-phosphate buffer, pH 7.0, containing 0.02 % (w/v) NaN3. Fractions of 8 ml were collected. Fractions containing kallikrein-binding activity were eluted at about 0.1 M NaCl. These fractions were pooled, concentrated and were dialysed against 20 mM sodium phosphate, pH 7.0. The dialysate was loaded onto a hydroxyapatite Bio-Gel HPHT column (1 cm x 5 cm) that had been equilibrated with the same buffer on a Pharmacia LKB f.p.l.c. system. After washing, the column was eluted with 60 ml of gradient from 20 mM sodium phosphate, pH 7.0 to 1 M NaCl in 0.3 M sodium-phosphate buffer, pH 7.0. Fractions with kallikrein-binding activity were pooled, dialysed against 25 mM Tris base (adjusted with iminodiacetic acid to pH 7.0) and applied onto a Mono P 5/5 column on an f.p.l.c. system. Recombinant RKBP was eluted at pH 4.8 as a single peak with 10% (w/v) polybuffer 74.
N-terminal amino-acid sequence analysis The purified RKBP was subjected to SDS/PAGE under reducing conditions and was electrotransferred onto an Immobilon-P membrane. The protein blotted onto the membrane was stained with 0.2 % (w/v) Ponceau S in 3 % (w/v) trichloroacetic acid for 1 mmn and destained with 1 M acetic acid for 2 min. RKBP was cut out and was subjected to Edman degradations performed with an Applied Biosystems Inc. model 477 gas-phase sequencer equipped with an on-line narrow-bore phenylthiohydantoin derivative analyser (Lu et al., 1989) .
Kallikrein-RKBP complex formation
Aliquots of the cell extract or of purified RKBP were-incubated with 1261-labelled kallikrein (10000 c.p.m.) in 10 mM sodium phosphate, pH 7.0, at 37°C for 1 h, as described previously (Chao and Chao, 1988) . The binding was stopped by adding onethird volume of 3 x SDS sample buffer (0.125 M Tris/HCl, pH 6.8, 30 % (v/v) glycerol and 5 % (w/v) SDS) and boiling for 5 min. The mixture was then resolved in SDS/PAGE under nonreducing conditions and was stained with Coomassie Blue, as described above. The gel was dried and was exposed to Kodak X-Omat film.
RESULTS
Expression and purfflcation of recombinant RKBP from E. coli RKBP was expressed with the T7 polymerase/promoter system and an E. coli lysate was prepared as described in the Experimental section. Soluble proteins were separated from the cell debris and from insoluble protein by ultracentrifugation, and resolved on SDS/PAGE under reducing conditions. The cell extract from HBlO1 cells harbouring the pET3b vector without the RKBP cDNA insert was applied onto SDS/PAGE as a control. As shown by Coomassie Blue staining in Figure 2 in Western-blot analysis as a single band (Figure 3, lane 1) . To determine the yield of the recombinant protein, the concentration of RKBP in the crude E. coli extract was measured by a specific e.l.i.s.a. using a polyclonal antibody against the native RKBP ( Figure 4) and the formation of high-molecular-mass complexes was A examined. Incubation of an aliquot of the cell extract with 1251-labelled rat tissue kallikrein resulted in the formation of an SDSstable high-molecular-mass complex in the cells expressing RKBP, but not in the pET3b control. This result suggests that the kallikrein-binding activity derives from the recombinant RKBP, rather than components of the E. coli extracts. Recombinant RKBP was purified by DEAE-Sepharose CL-6B hydroxyapatite Bio-Gel HPHT and Mono P 5/5 column chromatography as described in the Experimental section. The fractions after each purification step were resolved on SDS/PAGE under reducing conditions and were stained with Coomassie Blue as shown in Figure 5 . After the Mono P 5/5 column treatment, RKBP appeared to be homogenous in N-terminal sequence analysis of the recombinant RKBP To verify the fidelity of the expression, purified recombinant RKBP was subjected to N-terminal amino-acid sequencing. The sequence ofthe N-terminal ten amino-acid residues was obtained.
As shown in Table 1 , the amino-acid sequence of recombinant RKBP matches the N-terminal sequence of the native RKBP, except for one additional Met residue at the N-terminus of the recombinant protein. The additional Met is encoded by the imported ATG translational initiation codon in RKBP cDNA. This result confirmed the authenticity of the recombinant RKBP and the accuracy of the expression.
Immunological characteristics
To confirm the immunological identity of the recombinant protein produced by E. coli with native RKBP, both crude cell extracts and purified recombinant RKBP were subjected to Western-blot analysis using an anti-RKBP polyclonal antibody. Figure 3 shows that the recombinant RKBP was recognized by anti-RKBP antibody as single bands in the crude E. coli extract (lane 1), DEAE column fractions (lane 2) and Mono P column purified recombinant RKBP (lane 3). The immunoreactive RKBP had a molecular mass of 43 kDa (Figure 3, lanes 1-3) , which is consistent with the molecular mass of the purified recombinant protein stained with Coomassie Blue, as seen in SDS/PAGE ( Figure 5, lane 6) . The E. coli extract containing pET3b vector alone was used as a control in the Western-blot analysis and no E. coli component was recognized by the anti-RKBP antibody (Figure 3, lane 4) .
The immunological identity of the native and recombinant RKBPs was further examined by an e.l.i.s.a. using a polyclonal antibody against native RKBP. Both native and recombinant RKBPs were diluted serially and were measured by e.l.i.s.a. as described above. The A414 of each dilution was plotted as a function of protein concentration to give a dilution curve. As shown in Figure 4 , the linear dose-dependent curve for the recombinant RKBP is parallel with the native RKBP standard curve, indicating their immunological identity (Figure 4 ). There was no cross-reactivity between anti-RKBP antibody and other serine proteinase inhibitors in the e.l.i.s.a.
Biochemical characterization of recombinant RKBP The biochemical properties of the recombinant RKBP were compared with those of the native protein, as shown in Table 1 . They differ both in molecular mass and in charge. The native protein has a molecular mass of 60 kDa while the recombinant RKBP has a molecular mass of 43 kDa, which is very close to the calculated value for RKBP (44.6 kDa), based on the translated amino-acid sequence, and to the molecular mass of the deglycosylated RKBP (45 kDa), as reported by Pages et al. (1990) . The isoelectric point of the recombinant RKBP is pH 4.8-5.2, as determined by isoelectric focusing. The pl of the recombinant RKBP was also calculated at 5.2, using the GCG program. Native RKBP has a lower pl value, pH 4.2-4.6 ). These differences may be attributed to the lack of glycosylation in E. coli-expressed proteins.
In order to examine its enzyme-binding specificity, purified recombinant RKBP was subjected to a kallikrein-binding assay as described in the Experimental section. The recombinant and native RKBPs were incubated with '2I-labelled rat tissue kallikrein (rKl), tonin (rK2), S3 protein (rK9) and T-kininogenase (rK10), respectively, and the complex formation was examined. As shown in Figure 6 (a), after incubation with 125I-labelled rat Figure 6 Complex formaton of RKBP with kalllkrelns 1251-labelled rat tissue kallikrein (a) or T-kininogenase (b) were incubated with purified recombinant and native RKBP followed by SDS/PAGE under non-reducing conditions. The highmolecular-mass complexes of recombinant RKBP with rat tissue kallikrein or with Tkininogenase were visualized by autoradiography. . The recombinant and native RKBPs have identical N-terminal amino-acid sequences and immunological properties. However they showed differences in their size and charge. These differences may be ascribed to a lack of protein-glycosylation machinery in E. coli. Native RKBP contains five potential glycosylation sites, according to the consensus sequence . Since glycosylation alters the pl value of the protein by introducing carbohydrate moieties to some amino-acid residues, native RKBP has a lower pl value than the recombinant RKBP. As the result of the glycosylation the molecular mass of the native protein is higher than that of the recombinant RKBP, which results in the different molecular masses of their complexes with tissue kallikrein (rKl) and T-kininogenase (rK10).
Like native RKBP, recombinant RKBP can form SDS-and heat-stable complexes with rat tissue kallikrein (rKl) and with Tkininogenase (rK10) in vitro. Both tissue kallikrein and Tkininogenase are serine proteases that function via limited proteolysis of their specific kininogen substrates (Chagas et al., 1992) . In rat, tissue kallikrein cleaves both low-and highmolecular-mass kininogens to release vasoactive bradykinin (Kato et al., 1985) . T-kininogenase processes T-kininogen and releases T-kinin (Barlas et al., 1987) . Previous studies showed that rat tissue kallikrein is expressed in the kidney and the submandibular gland (Ashley and MacDonald, 1985) . Our recent results indicate that T-kininogenase is also expressed both in the kidney and in the submandibular gland (Ma et al., 1992 .
The binding of kallikrein-binding protein with its target serine proteases is enzyme-specific. Both recombinant and native RKBP showed strong binding with two kallikrein gene family members, tissue kallikrein (rKl) and T-kininogenase (rK10), but not with other members, such as tonin (rK2) and S3 protein (rK9). Rat tissue kallikrein, T-kininogenase, tonin and S3 protein belong to the rat tissue kallikrein gene family. They share more than 80 % amino-acid sequence similarity and have a similar tertiary protein structure (Bode et al., 1983; Wines et al., 1991) . Despite the similarity of structure, they have divergent substrate specificities because of divergent key amino-acid residues (Elmoujahed et al., 1990; Gutman et al., 1991; Chagas et al., 1992) . T-kininogenase retains all the key amino-acid residues contributing to the substrate-binding preference of tissue kallikrein (Ma et al., 1992) , while tonin and S3 protein have distinct substrate-binding pockets from that of tissue kallikrein (Ashley and MacDonald, 1985) . As a result tonin and S3 protein have very different substrate-binding specificities from tissue kallikrein Moreau et al., 1992) . Whether the differences in these key residues accounts for the fact that RKBP binds to tissue kallikrein and to T-kininogenase, but not to tonin and S3 protein remains to be investigated.
Kallikrein-binding protein shares a high structural similarity with human al-antitrypsin and acl-antichymotrypsin (Chai et al., 1991; Zhou et al., 1992) . However, they have shown distinct binding specificities toward their target proteases. The different enzyme-binding specificities may be determined by the divergent amino-acid residues in their reactive centres Chai et al., 1991) . It will be interesting to evaluate the altered proteinase-binding specificity of RKBP after the substitution of amino-acid residues at its reactive site. This RKBP expression system provides a basis for studying the interactions of kallikrein with its specific inhibitors. It establishes also a system for studying the structure-function relationships of RKBP through sitedirected mutagenesis.
